作者
Andrew S Bomback, Abhijit V Kshirsagar, M Ahinee Amamoo, Philip J Klemmer
发表日期
2008/2/1
来源
American Journal of Kidney Diseases
卷号
51
期号
2
页码范围
199-211
出版商
WB Saunders
简介
BACKGROUND
The use of mineralocorticoid receptor blockers (MRBs) in patients with chronic kidney disease is growing, but data for efficacy in decreasing proteinuria are limited by a relative paucity of studies, many of which are small and uncontrolled.
STUDY DESIGN
We performed a systematic review using the MEDLINE database (inception to November 1, 2006), abstracts from national meetings, and selected reference lists.
SETTING & POPULATION
Adult patients with chronic kidney disease and proteinuria.
SELECTION CRITERIA FOR STUDIES
English-language studies investigating the use of MRBs added to long-term angiotensin-converting enzyme (ACE)-inhibitor and/or angiotensin receptor blocker (ARB) therapy in adult patients with proteinuric kidney disease.
INTERVENTION
MRBs as additive therapy to conventional renin-angiotensin-aldosterone system blockade in patients with chronic kidney …
引用总数
学术搜索中的文章
AS Bomback, AV Kshirsagar, MA Amamoo… - American Journal of Kidney Diseases, 2008
